News of the rebranding, which will see the contract manufacturing organisation (CMO) renamed Boehringer Ingelheim BioXcellence, emerged this week at BIO 2012. The company has also set up a dedicated website for BioXcellence.
“Boehringer Ingelheim BioXcellence will help our customers and the market identify with the quality and reliability which has made Boehringer Ingelheim’s biopharmaceutical contract manufacturing business one of the largest in the world,” Simon Sturge, SVP of biopharmaceuticals at BI, said.